EPZM
Epizyme Inc
Epizyme Inc historical holders
total: 1
Muhlenkamp & Co Epizyme Inc transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2015 Q1
- Held for:
- 4 quarters
- Latest activity:
- 2016 Q1
Ronald Muhlenkamp has been an institutional investor in Epizyme Inc (EPZM) since 2015 Q1. According to 2026 Q1 report, Ronald Muhlenkamp doesn't hold any shares. The fund/company first acquired EPZM in 2015 Q1, initially purchasing 51,860 shares. Since the initial investment, Muhlenkamp & Co has made 3 more transactions in this position.
When did Ronald Muhlenkamp exit their EPZM position?
Ronald Muhlenkamp no longer holds Epizyme Inc (EPZM). They sold off their entire position in 2016 Q1, closing out an investment that began in 2015 Q1.
When did Ronald Muhlenkamp first invest in EPZM?
Ronald Muhlenkamp first invested in Epizyme Inc (EPZM) in 2015 Q1 at the reported quarter-end price of $18.78 per share, acquiring 51,860 shares in their initial purchase.
What is Ronald Muhlenkamp's average cost basis for EPZM?
Based on historical transaction data, Ronald Muhlenkamp's estimated cost basis for Epizyme Inc (EPZM) is approximately $18.72 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $18.72
- Weighted AVG sell price:
- $16.02
EPZM transactions history by Muhlenkamp & Co
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2016 Q1
|
0.00%
|
$16.02
|
-100% (-50,000)
|
|||
|
2015 Q4
|
0.25%
|
$16.02
|
-4.53% (-2,370)
|
|||
|
2015 Q3
|
0.21%
|
$12.85
|
+0.98% (+510)
|
|||
|
2015 Q1
|
0.21%
|
$18.78
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.